Michael Lattanzi
Memorial Sloan Kettering Cancer Center
ORCID: 0000-0002-6500-4753Also affiliated with Texas Oncology
Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Indexed papers
Why this DataRank?
An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.
Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.
Read the full methodology →Top data-sharing exemplar
The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.
Michal Sarfaty, Min Yuen Teo, Neha Ratna, Cihan Düzgöl, Samuel A. Funt +18 more
Papers
Driven by 4 papers — median percentile 88. Top paper: “Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial”.
Michael Lattanzi, Karissa Whiting, Hikmat Al‐Ahmadie, Colleen Quinlan, Min Yuen Teo +34 more
Michal Sarfaty, Min Yuen Teo, Neha Ratna, Cihan Düzgöl, Samuel A. Funt +18 more
Jatin Gandhi, Min Yuen Teo, Michael Lattanzi, Samuel A. Funt, David H. Aggen +14 more
Alexander Solovyov, Jayon Lihm, Colleen Quinlan, Karissa Whiting, Hao Li +15 more